AbbVie Inc. is a solid hold despite Humira sales decline. Explore growth opportunities in Skyrizi, Rinvoq, and the obesity ...
Factor performance was positive for the year but skewed negative during Q4 2024 when valuation and quality measures underperformed. Click here to read the full commentary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback